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Abstract: In vitro culture systems were used to assess the growth inhibition of kinetoplastids by a variety of aminoglycosides. The
parasites were allowed to grow to the stationary phase in the presence of varying concentrations of the drugs. The IC-50 for every
drug was calculated by comparison with the control. The sensitivity of various leishmanial strains to these drugs was in the order of:
G418 > hygromycin > paromomycin > neomycin; however, under our assay conditions gentamycin and kanamycin were nonleishmanicidal. The effects of the drugs on the intracellular form of the parasite in the macrophage cell line were also tested. Other
kinetoplastids, such as Crithidia spp., and Blastocrithidia culicis, were tested and showed resistance to all these drugs. Secondary
structures for the 3’ region of the SSUrRNA genes for these organisms were constructed, and correlations between drug sensitivity
and the secondary structures are presented. In Leishmania it is a T-A pair in the secondary structure instead of a C-G pair at position
1409-1491 (E. coli), as reported in other organisms, which is responsible for paromomycin sensitivity. The residue responsible for
hygromycin sensitivity remained G(1494). The 3’ loop-stem U-structures are different for organisms in this family, which might be
of significance in determining the overall sensitivity to these aminoglycosides. This might provide rational approaches to the
development of drugs specific for Leishmania. Because of the sensitivity of mammalian cells to this drug, we suggest that
paromomycin may be used for testing against leishmaniasis.
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Kinetoplastidlerin Aminoglikozide Duyarlılıkları: rRNA Geninin
Küçük Alt Biriminin 3’ Bölgesi ile İlgisi
Özet: Kinetoplastidlerin bir seri aminoglikozidlerce büyümesinin engellenmesi için in-vitro kültür sistemleri kullanılmıştır. İlacın çeşitli
derişimlerinin varlığında parazitler durgun faza kadar geliştirilmişlerdir. Her ilacın IC-50 değeri kontrolle karşılaştırılarak
hesaplanmıştır. Çeşitli leishmanial suşların ilaca olan duyarlılığı sırasıyla G418> Hygromycin> Paromomycin> Neomycin şeklindedir.
Buna rağmen bizim koşularımızda Gentamycin ve Kanamycin nonleishmanicidal bulunmuşlardır. İlacın parazitin makrofaj hücre
hattındaki hücre içi formuna olan etkisi de denenmiştir. Crithidia spp., ve Blastocrithida culicis gibi kinetoplastidler de denenmiş ve
tüm bu ilaçlara dayanıklı bulunmuştur. Bu organizmalar için SSUr-RNA genlerinin 3' bölgeleri için ikincil yapılar oluşturulmuştur.
Leishmania’ da ikincil yapıda diğer organizmalarda Paromomycin duyarlılığından sorumlu olduğu bildirilen 1409-1491 (E. coli)
pozisyonunda C-6 yerine T-A baz eşleşmesi bulunur. Higromisin duyarlılığı için görevli kök G(1494) olarak kalmıştır. Bu ailenin
organizmaları için 3’ loop-stem U-yapıları farklıdır ve bu aminoglikozidlere tüm duyarlılığı belirlemede önemli olabilirler. Bu ise
leishmania’ ya özgü ilaçların geliştirilmesinde gerçekçi yaklaşımlar sağlayabilir. Memeli hücrelerinin bu ilaca olan duyarlılıkları
yüzünden leishmaniasisin test edilmesinde paramomisinin kullanılmasını önerebiliriz.
Anahtar Sözcükler: Kinetoplastid, aminoglikozide, ssurRNA, Leishmania

Introduction
The current state of chemotherapy for leishmaniasis is
more promising than it has been for several years due to
both new drugs and new formulations of old drugs, either
recently approved or in clinical trial (1). In the past decade
4 new potential therapies for visceral leishmaniasis (VL)

have been introduced: a parenteral formulation of
aminosidine (paromomycin) (2), amphotericin B liposome
(3,4), and the orally active drug miltefosine (5,6) and
sitamaquine (6). Treatment of cutaneous leishmaniasis
(CL) has been improved by various topical formulations of
paromomycin (7-9) and oral miltefosine can also be
beneficial (10).
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Several other drugs, including itraconazole,
ketoconazole, dapsone, and allopurinol, have been tested
in limited clinical trials, often with equivocal results. Drug
treatment is complicated by the variation in sensitivity of
Leishmania species, different disease manifestations, lack
of controlled clinical trials of new (and old) drugs for CL,
and more recently, increasing levels of antimonial
resistance. This paper examines the problems that
produce variation in drug sensitivity (paromomycin), tries
to separate them from acquired drug resistance, and
finally discusses methods of monitoring resistance.
Aminoglycoside antibiotics exert their effect primarily
by interacting with small subunit ribosomal RNA
(SSUrRNA) (11-14). The 3’ region of SSUrRNA plays a
crucial role in protein biosynthesis (15-19). Its gene,
universally present in all organisms, is an extremely useful
tool for phylogeny (20). More than 2000 SSUrRNA genes
have been sequenced (21), including those of Crithidia
spp. and Blastocrithidia culicis, as recently reported from
our laboratory.
The aminoglycoside antibiotic paromomycin is a
potent antileishmanial agent (22). The World Health
Organization (WHO) is conducting clinical trials of
paromomycin ointment in various countries as a topical
therapy for cutaneous lesions in humans. A similar kind of
study is underway in Pakistan, where cutaneous
leishmaniasis is endemic (11-14). A 12% paromomycin
ointment supplied by the WHO was tested in human
volunteer patients and preliminary data obtained revealed
encouraging results.
Current chemotherapy for leishmaniasis also employs
heavy metal compounds (antimony and arsenic) and the
antibiotic amphotericin B, all of which induce toxic side
effects in the host. The aminoglycoside antibiotic
aminosidine (paromomycin) has recently shown some
promise, although its drawbacks are poor penetration and
the inducement of painful inflammation in some cases
(23). To the best of our knowledge this is the first report
of the use of aminoglycosides as potential antiparasitic
drugs, specifically against an intracellular parasite.
Due to the considerable clinical importance of
paromomycin, the mode of action of this antibiotic is
being studied by various researchers. Interference with
protein biosynthesis or direct action on ribosomes is the
main target of a large group of antibiotics (21). The
SSUrRNA gene, universally present in all organisms, is an
extremely useful tool for phylogeny (24). The 3’ region of
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SSUrRNA plays a crucial role in protein biosynthesis and
has been characterized as the site of action of several
aminoglycoside antibiotics.
In the case of paromomycin’s interaction with E. coli,
it has been established that the base pair at position 1409
(C) and 1491 (G) in the 3’ loop-stem U structure of the
secondary structure of SSUrRNA is involved. Resistance to
this aminoglycoside occurs in mutants in which this
particular base pair is disrupted [(A) itself] (25). This was
established in cases of other organisms, such as Giardia
Lamblia [(B) itself] (25) and Tetrahymena thermophila
[(C) itself] (26). In the case of Leishmania, Fong et al.
developed paromomycin-resistant clones in which there
was no mutation at the 1409-1491 equivalent position of
SSUrRNA (27); however, Mearouf et al. (28) recently
reported Leishmania resistance to paromomycin.
We used in vitro culture systems to assess the growth
inhibition of Kinetoplastids by a variety of
aminoglycosides. The effect of paromomycin, in
particular, on intracellular Leishmania in the in vitro
culture and of its topical ointment in treating cutaneous
lesions in human volunteers was studied. The 3’ region of
the secondary structure of these Kinetoplastids was
analyzed and then correlated with the experimental
determination of drug susceptibility.
Materials and Methods
The aminoglycoside antibiotics (paromomycin 1,
neomycin complex 2, kanamycin A 3, gentamycin A 4,
geneticin 5) were obtained from Sigma, USA and some of
them were synthesized by known procedures, parasite
cultures, and macrophage infection; L. amazonensis
(LV78), L. major (MHOM/PK/88/DESTO), L. tropica, and
L. infantum were maintained in the in vitro culture. They
were grown at 25 °C in medium 199 at pH 7.4 with 25
μM HEPES (N-2-hydroethylpiperazine-N-2-ethanesulfonic
acid) and 20% heat inactivated fetal bovine serum
(HIFBS) supplemented with the antibiotics penicillin (100 U
ml-1) and streptomycin (100 μg ml-1). Crithidia spp. and
Blastocrithidia culicis were cultured in brain heart infusion
medium. To study the effect of aminoglycosides on
promastigotes in culture, 4 106 promastigotes of the
respective Leishmania isolates were grown in the abovestated medium in the presence and absence of the drug.
After 5 days the promastigotes were counted in both
experimental and control groups, and the percentage of
growth inhibition was calculated. For studying the effect
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of the drugs on intracellular parasites, the permanent cell
line of mouse macrophage J774G8 was used. The
macrophages were cultured in medium RPMI 1640 with
HEPES (25 μM, pH 7.3), which contained 20% heat
inactivated fetal bovine serum and antibiotics.
Macrophages (cell density: 106/flask) were infected with
stationary phase promastigotes at a rate of 5 parasites
per macrophage, and after 24 h the infectivity was over
80%. The infected macrophages were washed by
replacing the old medium with fresh culture medium in
the absence (control) or presence of different
concentrations of the drugs. After 4 days the total
number of amastigotes in 100 macrophages was
determined as under, with each reading taken as a mean
of 3 experiments.
The 15% paromomycin simple ointment that
contained 12% benzethonium chloride was prepared
according to B.P. The ointment was applied on the
cutaneous lesion twice daily for 15 days.
Secondary Structure Construction: The Leishmania
SSUrRNA gene sequences came from GenBank. The
different strains had > 90% homology and were identical
in the 3’ U-loop region. The SSUrRNA genes for Crithidia
spp., and Blastocrithidia culicis were recently sequenced.
The secondary structures were constructed with the
LoopDLoop program (Don Gilbert, Indiana University,
USA). Numbering is according to that of E. coli.
Cell Culture: Leishmania cells were cultured in M199
plus 10% fetal bovine serum. Four species of Leishmania
were used: L. major, L. amazonesis, L. tropica, and L.
infantum. Crithidia spp. and Blastocrithidia culicis were
cultured in brain heart infusion medium.

Results and Discussion
Activity of the Drug against Promastigotes in
Culture
The antileishmanial activity of various aminoglycosides
against the old world and new world Leishmania isolates
is shown in Figures 1 and 2. The potency of the 4 drugs
was in the order of geneticin > hygromycin >
paromomycin > neomycin sulphate. Their ED50 values
ranged between 1.0 μg/ml for geneticin to about 30 μg/ml
for neomycin sulphate. Some of the cells transfected with
NEO were resistant to the drugs. In the present staudy
gentamycin and kanamycin showed no leishmanicidal
activity up to the concentration of about 200 μg/ml,

which is in agreement with El-On et al. (12,13). The
results presented in Figures 1 and 2 show the response of
the drug varied from strain to strain, signifying the
speciation of the parasite for chemotherapeutic purposes.
Effect of
Amastigotes

Paromomycin

on

Intracellular

Only the effect that produced successful infection of
the murine J 774 G8 macrophage cell line for L.
amazonensis strain was studied. The infected
macrophages were treated with different quantities of
paromomycin; at a concentration of 12 μg/ml of
paromomycin the intracellular amastigotes decreased by
> 50%. Addition of the drugs in fresh medium further
reduced the number of intracellular parasites, bringing
the ED50 value to about 3 μg/ml of paromomycin.
Treatment of Cutaneous Lesions in Human
Volunteer Patients with Paromomycin Ointment
To test the efficacy of the paromomycin ointment in
treating cutaneous lesions, 2 patients with
parasitologically confirmed cutaneous lesions were
treated twice daily for 15 days. On the eighth day the
inoculum from the lesion did not give a positive culture.
Between 40 and 50 days the lesions were totally cured.
Figures 1 and 2 show the results of such an experiment
in 1 patient.
Correlation of Drug Sensitivity Data with the
SSUrRNA Sequence
In Leishmania we attempted to correlate the antibiotic
susceptibility pattern with the secondary structure
prediction. The nucleotide sequence corresponding to the
3’ region of the SSUrRNA in Leishmania, Crithidia, and
Blastocrithidia are shown in Figure 3.
Paromomycin-resistant rRNA mutations have been
isolated in E. coli (11,30), Giardia (25), tetrahymena
(26), and yeast mitochondria (31), as outlined in Figure
2. These mutations are at the sites C-1409 and G-1491,
pairing at the circular location in the secondary structure.
Comparing the secondary structure of our tested
organisms with that of E. coli and Giardia, we found that
T-1409 and A-1491 exists in these organisms, strongly
suggesting that it may not be the individual bases at these
positions, but rather that the disruption of the pair may
account for paromomycin resistance. In Leishmania,
therefore, this T-A (1409-1491) confers susceptibility to
paromomycin. Hygromycin-resistant mutants of
tetrahymena, in which U-1495 is altered, have been
169
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Figure 1. The structure of paromomycin 1, its bioactive conformation with relevant nucleotides in the A-site binding domain and the proposed site
for diversification (solid arrow), neomycin complex 2, kanamycin A 3, gentamycin A 4, geneticin 5,. The dashed arrow indicates the
replacement of -OH by -NH2 for paromomycin 1 into neomycin 2.

isolated (26). This is also present in the kinetoplastids
studied; therefore, susceptibility can be predicted as
evidenced by the in vitro studies of the effects of this
drug. Chemical probing experiments with E. coli have
shown that A-1408 and G-1495 are protected by
neomycin antibiotics (11-14). At position 1408 in
Leishmania A is replaced with base G, while base G at
position 1494 is present, which may account for the low
susceptibility of kinetoplastids to neomycin, as evidenced
by the in vitro experiment results on Leishmania.
Kanamycin was observed to bind G at position 1408.
In our kinetoplastid the A at position 1408 was
replaced with G, except in Blastocrithidia; therefore, on
the basis of the gene structure the resistance to this drug
can be predicted and this is supported by the in vitro
Leishmania experiment results. The resistance of Crithidia
and Blastocrithidia to these drugs can be presumably
explained as such: they either do not take in these drugs
170

or their MDR efflux pump rapidly pumps out the drugs
before any damage is done to the cells. We have
constructed the secondary structure for other organisms
(Endotrypanum,
Bodo
caudatus,
Leptomonas,
Trypanosoma cruzi, and Trypanosoma brucei) in this
group as well. All the essential residues of this family are
the same.
To further substantiate the drug sensitivity test at the
molecular level, we constructed the secondary structure
of the 3’ region of the SSUrRNA gene, as outlined in
Figure 2, which is responsible for the sensitivity to these
drugs in all these organisms. After comparing the
secondary structures with that of E. coli (11-14) and
Giardia, we determined that at position 1409 and 1491,
a new T-A pair was formed instead of C-G, as in Giardia.
Previously, disruption of this pair also resulted in
resistance.
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Figure 2. The shape of Leishmania SSUrRNA.
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Figure 3. Diagrammatic model for higher-order organization of editing
complexes. The L-complex is shown as a dimer for which the
evidence is suggestive, and the 3 complexes are shown to
interact via RNA. The gRNA and mRNA indicated are the most
likely candidates, but the existence of other RNA species has
not been ruled out. The gRNA structure shown is taken from
the model given by Hermann et al. (29).

Paromomycin and Tetrahymena thermophila
In humans, G at position 1491 is substituted by A and
disrupts the paring (23) so that the base pairing rather
than G or C at those particular residues is responsible for
the paromomycin binding (22). For hygromycin, we
observed that G is at position 1494 in these organisms,
the same as in E. coli and Giardia, which is supposed to
bind to the drug (11). It is T that followed, which was
also shown to be the residue responsible for the drug
effect (21,22). These accounted for the hygromycin
susceptibility of these organisms. The residue responsible
for kanamycin sensitivity is G at position 1408 in these
organisms, except in B. culicis, so they are as resistant to
drug as A. Actually, this Crithidia sp. failed to be inhibited
by all the drugs tested, i.e. arsenates and tunicamycin,
and they developed methotrexate resistance after a short
period of treatment. Their multi-drug resistance feature
requires further investigation.
In Leishmania the sensitivity pattern correlated well
with the secondary structure prediction. This gave us the
molecular basis for using these aminoglycosides in
chemotherapy for leishmaniasis. Hygromycin has no
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useful practical application in this case, as it does not
exhibit selective toxicity. The spectrum of its activity may
extend to all organisms because its target nucleosides are
universally conserved. Paromomycin is a potentially useful
anti-Leishmania agent. Understanding the mechanism of
this drug action is of great clinical significance, as
resistance may appear in patients during treatment. The
possibility of the existence of more than 1 mechanism
cannot be ignored. We observed that transfection of
Leishmania with the NEO gene renders them resistant to
all these drugs, as the substrate to the enzyme. Neomycin
phosphotransferase covers a board range, including
neomycins, paromomycin, kanamycin, and gentamycin. It
is possible that this kind of mechanism may exist in
Leishmania.

Conclusion
This manuscript described the susceptibility of several
kinetoplastid species to a small panel of aminoglycosides,
and correlated the results with rRNA sequence and
secondary structure analysis. While the data are sound,
they are sufficiently novel, even though similar research
previously demonstrated the efficacy of paromomycin for
the treatment of cutaneous leishmaniasis.
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